PrEP/HIV drugs- Brands and Industry drivers
To identify pharmaceutical companies which are investing in PrEP/HIV drugs and the decision-making drivers for the consumers to choose between brands, in order to develop a new business pitch.
Preliminary research indicates that even though there are various PrEP/HIV drugs available in the global market, very few of them are FDA approved. Below is an overview of our research on pharmaceutical companies working in the field of HIV prevention drugs and the major drivers in this segment:
- Truvada, manufactured by Gilead Sciences, was the first drug to be approved by FDA for use as PrEP. It is a single pill which is the combination of ARVs tenofovir and emtricitabine.
- In October 2019, FDA has approved another medication by California based Gilead Sciences, Descovy, designed to prevent people from becoming infected with HIV.
- Facing harsh criticism over the prices of the drug, Truvada, Gilead Sciences announced in May that it would release its patent on the drug next year.
- Mylan Pharmaceuticals produce the genetic version of PrEP/HIV drug, Ricovir EM, which can be bought for as little as one-tenth the cost of Gilead’s Truvada.
- However, this generic drug has not been approved by FDA for U.S markets.
Drivers of the Industry
- Cost is a focus point for the consumers of PrEP drugs and fewer than 200,000 of the 1.2 million eligible Americans are enrolled in a PrEP program due to financial burden. Hence, generic drugs with their cost-effectiveness has huge global market potential.
- Promotion of PrEP/HIV drugs as demedicalised service by the brands, which means being offered in the same way that condoms, lubricant are, in a non-medical context will help in creating more awareness and encouraging people to adopt this safe and effective method of prevention.
- In addition to this public search, we scanned our proprietary research database of over 1 million sources and were unable to find any specific research reports that address your goals.
Proposed next steps:
You need to be the project owner to select a next step.